Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 169 (10), 1015-20

Discontinuation of Benzodiazepines Among Older Insomniac Adults Treated With Cognitive-Behavioural Therapy Combined With Gradual Tapering: A Randomized Trial

Clinical Trial

Discontinuation of Benzodiazepines Among Older Insomniac Adults Treated With Cognitive-Behavioural Therapy Combined With Gradual Tapering: A Randomized Trial

Lucie Baillargeon et al. CMAJ.


Background: Long-term use of hypnotics is not recommended because of risks of dependency and adverse effects on health. The usual clinical management of benzodiazepine dependency is gradual tapering, but when used alone this method is not highly effective in achieving long-term discontinuation. We compared the efficacy of tapering plus cognitive-behavioural therapy for insomnia with tapering alone in reducing the use of hypnotics by older adults with insomnia.

Methods: People with chronic insomnia who had been taking a benzodiazepine every night for more than 3 months were recruited through media advertisements or were referred by their family doctors. They were randomly assigned to undergo either cognitive-behavioural therapy plus gradual tapering of the drug (combined treatment) or gradual tapering only. The cognitive-behavioural therapy was provided by a psychologist in 8 weekly small-group sessions. The tapering was supervised by a physician, who met weekly with each participant over an 8-week period. The main outcome measure was benzodiazepine discontinuation, confirmed by blood screening performed at each of 3 measurement points (immediately after completion of treatment and at 3- and 12-month follow-ups).

Results: Of the 344 potential participants, 65 (mean age 67.4 years) met the inclusion criteria and entered the study. The 2 study groups (35 subjects in the combined treatment group and 30 in the tapering group) were similar in terms of demographic characteristics, duration of insomnia and hypnotic dosage. Immediately after completion of treatment, a greater proportion of patients in the combined treatment group had withdrawn from benzodiazepine use completely (77% [26/34] v. 38% [11/29]; odds ratio [OR] 5.3, 95% confidence interval [CI] 1.8-16.2; OR after adjustment for initial benzodiazepine daily dose 7.9, 95% CI 2.4-30.9). At the 12-month follow-up, the favourable outcome persisted (70% [23/33] v. 24% [7/29]; OR 7.2, 95% CI 2.4-23.7; adjusted OR 7.6, 95% CI 2.5-26.6); similar results were obtained at 3 months.

Interpretation: A combination of cognitive-behavioural therapy and benzodiazepine tapering was superior to tapering alone in the management of patients with insomnia and chronic benzodiazepine use. The beneficial effects were sustained for up to 1 year. Applying this multidisciplinary approach in the community could help reduce benzodiazepine use by older people.


Fig. 1: Flow of patients through a randomized trial of cognitive-behavioural therapy combined with tapering of benzodiazepine use. In the combined treatment group, one patient who completed the treatment was lost to follow-up by the time of the 3-month evaluation. For one additional patient in this group, information about benzodiazepine withdrawal was obtained at 12-month follow-up, but data for the variable “dosage reduction of 50% or more” was not available at that time. Of the 6 subjects who did not complete the tapering-alone treatment, 5 agreed to be contacted at the 3-month and 12-month follow-ups to report on benzodiazepine cessation.

Comment in

Similar articles

See all similar articles

Cited by 36 articles

See all "Cited by" articles

Publication types

MeSH terms